Hypoxia inducible factor-1α (HIF-1α) in breast cancer: The crosstalk with oncogenic and onco-suppressor factors in regulation of cancer hallmarks.

Autor: Mirzaei S; Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran, Iran. Electronic address: sepidehmirzaei.smv@gmail.com., Ranjbar B; Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 14117-13116, Iran., Tackallou SH; Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran., Aref AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.
Jazyk: angličtina
Zdroj: Pathology, research and practice [Pathol Res Pract] 2023 Aug; Vol. 248, pp. 154676. Date of Electronic Publication: 2023 Jul 07.
DOI: 10.1016/j.prp.2023.154676
Abstrakt: Low oxygen level at tumor microenvironment leads to a condition, known as hypoxia that is implicated in cancer progression. Upon hypoxia, HIF-1α undergoes activation and due to its oncogenic function and interaction with other molecular pathways, promotes tumor progression. The HIF-1α role in regulating breast cancer progression is described, Overall, HIF-1α has upregulation in breast tumor and due to its tumor-promoting function, its upregulation is in favor of breast tumor progression. HIF-1α overexpression prevents apoptosis in breast tumor and it promotes cell cycle progression. Silencing HIF-1α triggers cycle arrest and decreases growth. Migration of breast tumor enhances by HIF-1α signaling and it mainly induces EMT in providing metastasis. HIF-1α upregulation stimulates drug resistance and radio-resistance in breast tumor. Furthermore, HIF-1α signaling induces immune evasion of breast cancer. Berberine and pharmacological intervention suppress HIF-1α signaling in breast tumor and regulation of HIF-1α by non-coding RNAs occurs. Furthermore, HIF-1α is a biomarker in clinic.
Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest.
(Copyright © 2023 Elsevier GmbH. All rights reserved.)
Databáze: MEDLINE